Business Description
Pila Pharma AB
ISIN : SE0015988274
Compare
Compare
Traded in other countries / regions
PILA.Sweden5KC.Germany IPO Date
2021-07-15Description
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.97 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.23 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.51 | |||||
| Beneish M-Score | -5.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1.2 | |||||
| 3-Year EPS without NRI Growth Rate | -13.1 | |||||
| 3-Year FCF Growth Rate | -22.9 | |||||
| 3-Year Book Growth Rate | 9.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.19 | |||||
| 9-Day RSI | 69.68 | |||||
| 14-Day RSI | 66.44 | |||||
| 6-1 Month Momentum % | 56.46 | |||||
| 12-1 Month Momentum % | -19.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.48 | |||||
| Quick Ratio | 3.48 | |||||
| Cash Ratio | 3.32 | |||||
| Days Sales Outstanding | 12.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -436.98 | |||||
| Net Margin % | -678.74 | |||||
| FCF Margin % | -331.78 | |||||
| ROE % | -198.52 | |||||
| ROA % | -147.46 | |||||
| ROIC % | -155.99 | |||||
| ROC (Joel Greenblatt) % | -989000 | |||||
| ROCE % | -197.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 38.89 | |||||
| PB Ratio | 10.01 | |||||
| Price-to-Tangible-Book | 14.74 | |||||
| EV-to-EBIT | -6.76 | |||||
| EV-to-EBITDA | -7.61 | |||||
| EV-to-Revenue | 45.77 | |||||
| EV-to-FCF | -11.89 | |||||
| Price-to-Net-Current-Asset-Value | 14.74 | |||||
| Price-to-Net-Cash | 16.47 | |||||
| Earnings Yield (Greenblatt) % | -14.77 | |||||
| FCF Yield % | -7.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pila Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 1.463 | ||
| EPS (TTM) (kr) | -0.47 | ||
| Beta | 0 | ||
| Volatility % | 108.28 | ||
| 14-Day RSI | 66.44 | ||
| 14-Day ATR (kr) | 0.313061 | ||
| 20-Day SMA (kr) | 2.431 | ||
| 12-1 Month Momentum % | -19.86 | ||
| 52-Week Range (kr) | 0.992 - 3.35 | ||
| Shares Outstanding (Mil) | 23.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pila Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pila Pharma AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pila Pharma AB Frequently Asked Questions
What is Pila Pharma AB(OSTO:PILA)'s stock price today?
The current price of OSTO:PILA is kr2.80. The 52 week high of OSTO:PILA is kr3.35 and 52 week low is kr0.99.
When is next earnings date of Pila Pharma AB(OSTO:PILA)?
The next earnings date of Pila Pharma AB(OSTO:PILA) is 2024-08-27.
Does Pila Pharma AB(OSTO:PILA) pay dividends? If so, how much?
Pila Pharma AB(OSTO:PILA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers